Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.

Journal of virology - 1 Apr 2007

Ray Neelanjana, Harrison Jessamina E, Blackburn Leslie A, Martin Jeffrey N, Deeks Steven G, Doms Robert W

Abstract excerpt

The clinical use of the human immunodeficiency virus (HIV) fusion inhibitor enfuvirtide (ENF) can select for drug-resistant HIV-1 strains bearing mutations in the HR1 region of the viral envelope (Env) protein. We analyzed the properties of multiple Env proteins isolated from five patients who experienced an initial decline in viral load after ENF therapy followed by subsequent rebound due to emergence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enfuvirtide

Share to Gene Products, env

Share to HIV Envelope Protein gp41

Share to Peptide Fragments

Share to Sensitivity and Specificity

Share to Virus Internalization

Source

Open in PubMed Open full text

Identifiers

PMID: 17251281
DOI: 10.1128/JVI.02413-06
PMCID: PMC1866075

Genes

CCR5
CXCR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.PMID 17251281Read ↗

Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.Semantic proximity Read ↗

Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.Semantic proximity Read ↗

Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.Semantic proximity Read ↗

HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to EnfuvirtideSemantic proximity Read ↗

In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations.Semantic proximity Read ↗

HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications.Semantic proximity Read ↗

Massively parallel profiling of HIV-1 resistance to the fusion inhibitor enfuvirtideSemantic proximity Read ↗

Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.Semantic proximity Read ↗

Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.Semantic proximity Read ↗

Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo.Semantic proximity Read ↗

Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.Semantic proximity Read ↗

A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.